Regeneron and Sanofi expand antibody alliance with $8bn deal
Regeneron Pharmaceuticals and Sanofi have announced a significant expansion of their two-decade antibody collaboration, adding four next-generation, long-acting candidates targeting the IL-4 and IL-13 pathways to an alliance that already underpins Dupixent, one of the world's most widely prescribed antibody medicines. Regeneron will receive a $1 billion upfront payment from Sanofi, with up to $7 billion in additional milestone payments, while the two companies will split development and commercialisation costs equally and share future profits on a 50:50 global basis.
The four new candidates are all Regeneron-invented. REGN20423, a long-acting IL-13 monoclonal antibody, is currently in a Phase 1 trial for atopic dermatitis. The remaining three, a long-acting IL-4xIL-13 bispecific antibody, an IL-4 antibody, and an antibody targeting IL-4 receptor alpha (IL-4Rα), are all at the preclinical stage and are expected to enter clinical studies in 2027. The existing profit-sharing arrangement covering Dupixent is unchanged.
Deal structure and pipeline logic
Regeneron will lead research and development across the new programmes; Sanofi will take responsibility for global commercial execution. The companies have also settled unspecified prior collaboration-related litigation, resolving a potential overhang on the partnership.
An option clause gives Regeneron the right to bring Sanofi's lunsekimig, an investigational bispecific Nanobody targeting TSLP and IL-13, into the collaboration once its Phase 3 programme in chronic obstructive pulmonary disease is complete. That provision signals the companies' intent to position the alliance as a platform for the next wave of type 2 inflammatory disease treatments, not merely an extension of the Dupixent franchise.
Regeneron chief executive Leonard Schleifer said the expansion was designed to replicate the global impact of Dupixent at pace. "By expanding our alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved," he said.
Market context and competitive landscape
The immunology biologics market is fiercely competitive. Dupixent currently serves more than 1.5 million patients across nine approved indications in over 60 countries, giving the Regeneron-Sanofi partnership an established commercial infrastructure that rivals would struggle to match at speed. AstraZeneca and AbbVie both have active type 2 inflammation programmes, and biosimilar pressure on older IL-4/IL-13 pathway agents is growing, making long-acting formulations an increasingly important differentiator.
The strategic rationale for long-acting antibodies is clear: monthly or less frequent dosing improves adherence, differentiates against reference products, and may support premium pricing in markets where payer scrutiny of biologics is intensifying. Regulators at the FDA and EMA have shown willingness to accept extrapolation from established mechanism classes when safety profiles are well characterised, which could shorten the path to approval for candidates that share the IL-4/IL-13 target space with Dupixent.
The deal also reflects Sanofi's stated ambition to reinvigorate its innovation pipeline. Chief executive Belén Garijo described the agreement as "a deliberate first step in igniting Sanofi's innovation engine," framing it as a cornerstone of the company's longer-term commercial strategy rather than an incremental portfolio addition.
For Regeneron, the $1 billion upfront provides meaningful non-dilutive capital. Investors will focus on Phase 1 data readouts for REGN20423 and the timeline for the other three candidates to reach the clinic in 2027, as well as on the eventual design of pivotal studies that will determine how aggressively the new cohort can challenge the established Dupixent label.